[go: up one dir, main page]

SG11201805066RA - Alkyl dihydroquinoline sulfonamide compounds - Google Patents

Alkyl dihydroquinoline sulfonamide compounds

Info

Publication number
SG11201805066RA
SG11201805066RA SG11201805066RA SG11201805066RA SG11201805066RA SG 11201805066R A SG11201805066R A SG 11201805066RA SG 11201805066R A SG11201805066R A SG 11201805066RA SG 11201805066R A SG11201805066R A SG 11201805066RA SG 11201805066R A SG11201805066R A SG 11201805066RA
Authority
SG
Singapore
Prior art keywords
international
street
amgen
compounds
massachusetts
Prior art date
Application number
SG11201805066RA
Other languages
English (en)
Inventor
Matthew Weiss
Benjamin C Milgram
Isaac E Marx
Thomas Dineen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG11201805066RA publication Critical patent/SG11201805066RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201805066RA 2015-12-18 2016-12-19 Alkyl dihydroquinoline sulfonamide compounds SG11201805066RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562269518P 2015-12-18 2015-12-18
PCT/US2016/067617 WO2017106871A1 (en) 2015-12-18 2016-12-19 Alkyl dihydroquinoline sulfonamide compounds

Publications (1)

Publication Number Publication Date
SG11201805066RA true SG11201805066RA (en) 2018-07-30

Family

ID=57758767

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805066RA SG11201805066RA (en) 2015-12-18 2016-12-19 Alkyl dihydroquinoline sulfonamide compounds

Country Status (23)

Country Link
US (2) US10383866B2 (es)
EP (1) EP3390392B1 (es)
JP (1) JP6903663B2 (es)
KR (1) KR102804113B1 (es)
CN (2) CN108602804B (es)
AU (1) AU2016369652B2 (es)
CA (1) CA3008484C (es)
CL (1) CL2018001631A1 (es)
CO (1) CO2018007436A2 (es)
CR (1) CR20180368A (es)
EA (1) EA038286B1 (es)
IL (1) IL259918B (es)
MA (1) MA44065A (es)
MX (1) MX377032B (es)
MY (1) MY197595A (es)
NZ (1) NZ743377A (es)
PE (1) PE20181328A1 (es)
PH (1) PH12018501285A1 (es)
SG (1) SG11201805066RA (es)
TN (1) TN2018000214A1 (es)
UA (1) UA122913C2 (es)
WO (1) WO2017106871A1 (es)
ZA (1) ZA201804033B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202246215A (zh) 2015-12-18 2022-12-01 美商亞德利克斯公司 作為非全身tgr5促效劑之經取代之4-苯基吡啶化合物
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
JP2021195367A (ja) 2020-06-10 2021-12-27 アムジエン・インコーポレーテツド シクロプロピルジヒドロキノリンスルホンアミド化合物
JP7739051B2 (ja) * 2020-06-10 2025-09-16 アムジエン・インコーポレーテツド シクロブチルジヒドロキノリンスルホンアミド化合物
EP4165032B1 (en) 2020-06-10 2025-04-16 Amgen Inc. Heteroalkyl dihydroquinoline sulfonamide compounds
CA3228542A1 (en) * 2021-08-12 2023-02-16 Tyk Medicines, Inc. Polycyclic compound and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
WO2010045197A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
JP2014521749A (ja) * 2011-08-17 2014-08-28 アムジエン・インコーポレーテツド ヘテロアリールナトリウムチャネル阻害剤
EP2788332A1 (en) * 2011-12-07 2014-10-15 Amgen, Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
US9051311B2 (en) 2012-03-09 2015-06-09 Amgen Inc. Sulfamide sodium channel inhibitors
US9776995B2 (en) * 2013-06-12 2017-10-03 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors

Also Published As

Publication number Publication date
US10383866B2 (en) 2019-08-20
EA038286B1 (ru) 2021-08-04
JP2019504016A (ja) 2019-02-14
BR112018012298A2 (pt) 2018-12-04
NZ743377A (en) 2022-05-27
CN119119017A (zh) 2024-12-13
MX377032B (es) 2025-03-07
KR20180094946A (ko) 2018-08-24
EP3390392A1 (en) 2018-10-24
JP6903663B2 (ja) 2021-07-14
US20200009129A1 (en) 2020-01-09
CA3008484A1 (en) 2017-06-22
WO2017106871A1 (en) 2017-06-22
TN2018000214A1 (en) 2019-10-04
CL2018001631A1 (es) 2018-09-28
CN108602804B (zh) 2025-05-02
ZA201804033B (en) 2019-04-24
PH12018501285A1 (en) 2019-02-04
EA201891319A1 (ru) 2018-11-30
EP3390392B1 (en) 2021-10-06
CR20180368A (es) 2018-09-28
MX2018007432A (es) 2018-09-21
AU2016369652B2 (en) 2020-10-22
CO2018007436A2 (es) 2018-07-19
MY197595A (en) 2023-06-27
CA3008484C (en) 2023-10-17
UA122913C2 (uk) 2021-01-20
US20180369227A1 (en) 2018-12-27
PE20181328A1 (es) 2018-08-20
CN108602804A (zh) 2018-09-28
AU2016369652A1 (en) 2018-06-28
KR102804113B1 (ko) 2025-05-09
IL259918A (en) 2018-07-31
MA44065A (fr) 2021-05-26
IL259918B (en) 2020-06-30

Similar Documents

Publication Publication Date Title
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201805066RA (en) Alkyl dihydroquinoline sulfonamide compounds
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201804132UA (en) Eif4-a-inhibiting compounds and methods related thereto
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201809082WA (en) Nlrp3 modulators
SG11201809751XA (en) Egfr inhibitor compounds
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201810561YA (en) Liquid neurotoxin formulation stabilized with tryptophan or tyrosine
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201811559WA (en) Cancer treatment combinations
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201908512YA (en) Somatostatin modulators and uses thereof